Liquid chromatography-tandem mass spectrometry analysis of erythrocyte thiopurine nucleotides and effect of thiopurine methyltransferase gene variants on these metabolites in patients receiving azathioprine/6-mercaptopurine therapy

Clinical Chemistry

Volumn 51, Issue 11, 2005, Pages 2074-2084

  Dervieux, Thierry ^a,d   Meyer, Gary ^a   Barham, Robert ^a   Matsutani, Mariko ^a   Barry, Mary ^a   Boulieu, Roselyne ^b   Neri, Bruce ^a   Seidmans, Ernest ^c  

^a Prometheus Laboratories   (United States)

^b UNIVERSITÉ LYON 1   (France)

^c MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^d Prometheus Laboratories   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; 6 METHYLMERCAPTOPURINE NUCLEOTIDE DERIVATIVE; 6 THIOGUANINE NUCLEOTIDE DERIVATIVE; 6 THIOGUANOSINE DIPHOSPHATE; 8 BROMOADENINE; ACETONITRILE; ADENINE DERIVATIVE; AMMONIUM ACETATE; AZATHIOPRINE; FORMIC ACID; MERCAPTOPURINE; METHYL 6 THIOINOSINE DIPHOSPHATE; METHYL 6 THIOINOSINE MONOPHOSPHATE; METHYL 6 THIOINOSINE TRIPHOSPHATE; NUCLEOTIDE DERIVATIVE; PERCHLORIC ACID; THIOGUANINE DERIVATIVE; THIOGUANOSINE PHOSPHATE; THIOPURINE METHYLTRANSFERASE; UNCLASSIFIED DRUG;

ACCURACY; ALLELE; ARTICLE; CHEMICAL REACTION; CONTROLLED STUDY; ENTERITIS; ERYTHROCYTE; EXTRACTION; GENE; GENE FREQUENCY; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HYDROLYSIS; IONIZATION; LEUKOPENIA; LIQUID CHROMATOGRAPHY; LIVER TOXICITY; METABOLITE; MONITORING; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TANDEM MASS SPECTROMETRY; TPMT GENE; ULTRAVIOLET IRRADIATION;

6-MERCAPTOPURINE; ADULT; AZATHIOPRINE; CHROMATOGRAPHY, LIQUID; COHORT STUDIES; DRUG THERAPY, COMBINATION; ERYTHROCYTES; FEMALE; GUANINE NUCLEOTIDES; HUMANS; HYDROLYSIS; INFLAMMATORY BOWEL DISEASES; MALE; MASS SPECTROMETRY; METHYLTRANSFERASES; PURINE NUCLEOTIDES; THIONUCLEOTIDES; VARIATION (GENETICS);

EID: 27444434760     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2005.050831     Document Type: Article

References (43)

1. Dubinsky MC, Lamothe S, Yang HY, Targan SR, Sinnett D, Theoret Y, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000;118:705-13.
2. Lennard L. The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol 1992;43:329-39.
3. Dervieux T, Blanco JG, Krynetski EY, Vanin EF, Roussel MF, Relling MV. Differing contribution of thiopurine methyltransferase to mercaptopurine versus thioguanine effects in human leukemic cells. Cancer Res 2001;61:5810-6.
4. Tiede I, Fritz G, Strand S, Poppe D, Dvorsky R, Strand D, et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest 2003;111:1133-45.
5. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980;32:651-62.
6. Honchel R, Aksoy IA, Szumlanski C, Wood TC, Otterness DM, Wieben ED, et al. Human thiopurine methyltransferase: molecular cloning and expression of T84 colon carcinoma cell cDNA. Mol Pharmacol 1993;43:878-87.
7. Szumlanski C, Otterness D, Her C, Lee D, Brandriff B, Kelsell D, et al. Thiopurine methyltransferase pharmacogenetics: human gene cloning and characterization of a common polymorphism. DNA Cell Biol 1996;15:17-30.
8. Yates CR, Krynetski EY, Loennechen T, Fessing MY, Tai HL, Pui C-H, et al. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med 1997;126:608-14.
9. Tai HL, Krynetski EY, Yates CR, Loennechen T, Fessing MY, et al. Thiopurine S-methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians. Am J Hum Genet 1996;58:694-702.
10. Tai HL, Krynetski EY, Schuetz EG, Yanishevski Y, Evans WE. Enhanced proteolysis of thiopurine S-methyltransferase (TPMT) encoded by mutant alleles in humans (TPMT*3A, TPMT*2): mechanisms for the genetic polymorphism of TPMT activity. Proc Natl Acad Sci U S A 1997;94:6444-9.
11. Tai H-L, Fessing M, Bonten EJ, Yanishevski Y, d'Azzo A, Krynetski E, et al. Enhanced proteasomal degradation of mutant human thiopurine S-methyltransferase (TPMT) in mammalian cells: mechanism for TPMT protein deficiency inherited by TPMT*2, TPMT*3A, TPMT*3B or TPMT*3C. Pharmacogenetics 1999;9:641-50.
12. Lennard L, Lilleyman JS, Van Loon J, Weinshilboum RM. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet 1990;336:225-9.
13. Lennard L, Gibson BE, Nicole T, Lilleyman JS. Congenital thiopurine methyltransferase deficiency and 6-mercaptopurine toxicity during treatment for acute lymphoblastic leukaemia. Arch Dis Child 1993;69:577-9.
14. Relling MV, Hancock ML, Rivera GK, Sandlund JT, Ribeiro RC, Krynetski EY, et al. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst 1999;91:2001-8.
15. Dervieux T, Medard Y, Verpillat P, Guigonis V, Duval M, Lescoeur B, et al. Possible implication of thiopurine S-methyltransferase in the occurrence of infectious episodes during maintenance therapy of acute leukemia with mercaptopurine. Leukemia 2001;15:1706-12.
16. Tassaneeyakul W, Srimarthpirom S, Reungjui S, Chansung K, Romphruk A. Azathioprine-induced fatal myelosuppression in a renal-transplant recipient who carried heterozygous TPMT*1/*3C. Transplantation 2003;76:265-6.
17. Nygaard U, Toft N, Schmiegelow K. Methylated metabolites of 6-mercaptopurine are associated with hepatotoxicity. Clin Pharmacol Ther 2004;75:274-81.
18. Dubinsky MC, Yang H, Hassard PV, Seidman EG, Kam LY, Abreu MT, et al. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 2002;122:904-15.
19. Cuffari C, Dassopoulos T, Turnbough L, Thompson RE, Bayless TM. Thiopurine methyltransferase activity influences clinical response to azathioprine in inflammatory bowel disease. Clin Gastroenterol Hepatol 2004;2:410-7.
20. Cuffari C, Theoret Y, Latour S, Seidman G. 6-Mercaptopurine metabolism in Crohn's disease: correlation with efficacy and toxicity. Gut 1996;39:401-6.
21. Lavi LE, Holcenberg JS. A rapid and sensitive high-performance liquid chromatographic assay for 6-mercaptopurine metabolites in red blood cells. Anal Biochem 1985;144:514-21.
22. Erdmann GR, France LA, Bostrom BC, Canafax DM. A reversed phase high performance liquid chromatography approach in determining total red blood cell concentrations of 6-thioguanine, 6-mercaptopurine, methylthioguanine, and methylmercaptopurine in a patient receiving thiopurine therapy. Biomed Chromatogr 1990;4:47-51.
23. Lennard L, Singleton HJ. High-performance liquid chromatographic assay of the methyl and nucleotide metabolites of 6-mercaptopurine: quantitation of red blood cell 6-thioguanine nucleotide, 6-thioinosinic acid and 6-methylmercaptopurine metabolites in a single sample. J Chromatogr 1992;583:83-90.
24. Dervieux, T, Boulieu R. Simultaneous determination of 6-thioguanine and methyl 6-mercaptopurine nucleotides of azathioprine in red blood cells by HPLC. Clin Chem 1998;44:551-5.
25. Erdmann Gr, Steury JC, Carleton BC, Stafford RJ, Bostrom BC, Canafax DM. Reversed-phase high-performance liquid chromatographic approach to determine total lymphocyte concentrations of 6-thioguanine, methylmercaptopurine and methylthioguanine in humans. J Chromatogr 1991;57:149-56.
26. Dervieux T, Boulieu R. Identification of 6-methylcaptopurine derivative formed during acid hydrolysis of thiopurine nucleotides in erythrocytes, using liquid chromatography-mass spectrometry, infrared spectroscopy, and nuclear magnetic resonance assay. Clin Chem 1998;44:2511-5.
27. Annesley TM. Ion suppression in mass spectrometry. Clin Chem 2003;49:1041-4.
28. Malkin S, Witton L, Theoret Y, Seidman E, Barstad P, Rose S. Performance evaluation of reversed phase HPLC assays for metabolite of mercaptopurine and azathioprine [Poster]. American College of Gastroenterology annual meeting, October 19-20, 1999, Phoenix, AZ.
29. Kitchen BJ, Moser A, Lowe E, Balis FM, Widemann B, Anderson L, et al. Thioguanine administered as a continuous intravenous infusion to pediatric patients is metabolized to the novel metabolite 8-hydroxy-thioguanine. J Pharmacol Exp Ther 1999;291:870-4.
30. Stefan C, Walsh W, Banka T, Adeli K, Verjee Z. Improved HPLC methodology for monitoring thiopurine metabolites in patients on thiopurine therapy. Clin Biochem 2004;37:764-71.
31. Shipkova M, Armstrong VW, Wieland E, Oellerich M. Differences in nucleotide hydrolysis contribute to the differences between erythrocyte 6-thioguanine nucleotide concentrations determined by two widely used methods. Clin Chem 2003;49:260-8.
32. Armstrong VW, Shipkova M, von Ahsen N, Oellerich M. Analytic aspects of monitoring therapy with thiopurine medications. Ther Drug Monit 2004;26:220-6.
33. Collie-Duguid ES, Pritchard SC, Powrie RH, Sludden J, Li T, McLeod HL. The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations. Pharmacogenetics 1999;9:37-42.
34. McLeod HL, Pritchard SC, Githang'a J, Indalo A, Ameyaw MM, Powrie RH, et al. Ethnic differences in thiopurine methyltransferase pharmacogenetics: evidence for allele specificity in Caucasian and Kenyan individuals. Pharmacogenetics 1999;9:773-6.
35. Zhang JP, Guan YY, Wu JH, Xu AL, Zhou S, Huang M. Phenotyping and genotyping study of thiopurine S-methyltransferase in healthy Chinese children: a comparison of Han and Yao ethnic groups. Br J Clin Pharmacol 2004;58:163-8.
36. von Ahsen N, Armstrong VW, Oellerich M. Rapid long-range molecular haplotyping of thiopurine S-mehtyltransferase (TPMT) *3A, *3B, and *C. Clin Chem 2004;50:1528-34.
37. McDonald OG, Krynetski EY, Evans WE. Molecular haplotyping of genomic DNA for multiple single-nucleotide polymorphisms located kilobases apart using long-range polymerase chain reaction and intramolecular ligation. Pharmacogenetics 2002;12:93-9.
38. Oh KT, Anis AH, Bae SC. Pharmacogenetics analysis of thiopurine methyltranferase polymorphism screening by polymerase chain reaction for treatment with azathioprine in Korea. Rheumatology (Oxford) 2004;43:156-63.
39. Marra CA, Esdaile JM, Anis AH. Practical pharmacogenetics: the cost effectiveness of screening for thiopurine s-methyltransferase polymorphisms in patients with rheumatological conditions treated with azathioprine. J Rheumatol 2002;29:2507-12.
40. Schutz E, Gummert J, Mohr FW, Armstrong VW, Oellerich M. Should 6-thioguanine nucleotides be monitored in heart transplant recipients given azathioprine? Ther Drug Monit 1996;18:228-33.
41. Leipold G, Schutz E, Haas JP, Oellerich M. Azathipprine-induced severe pancytopenia due to a homozygous two-pojnt mutation of the thiopurine methyltransferase gene in a patient with juvenile HLA-B27-associated spondylarthritis. Arthritis Rheum 1997;40:1896-8.
42. McLeod HL, Miller DR, Evans WE. Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient [Letter]. Lancet 1993;341:1151.
43. Boulieu R, Sauviat M, Dervieux T, Bertocchi M, Mornex JF. Phenotype determination of thiopurine methyltransferase in erythrocytes by HPLC. Clin Chem 2001;47:956-8.